For one-carbon donors, intravenous sodium formate or oral formate pro-drug regimens raise circulating formate and are sufficient to augment de novo purine synthesis in tumor-infiltrating CD8+ T cells, thereby synergizing with anti-PD-1 and improving tumor control and survival in multiple murine models [52, 70, 72]. The gene discussed is PDCD1; the disease is neoplasm.